- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT02979613
Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25 mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 3. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
-
London, Egyesült Királyság
-
London, Egyesült Királyság, E1 1BB
-
-
-
-
California
-
Los Angeles, California, Egyesült Államok
-
Palo Alto, California, Egyesült Államok
-
Pasadena, California, Egyesült Államok
-
San Diego, California, Egyesült Államok
-
San Francisco, California, Egyesült Államok
-
San Jose, California, Egyesült Államok
-
-
Maryland
-
Baltimore, Maryland, Egyesült Államok
-
-
Massachusetts
-
Boston, Massachusetts, Egyesült Államok
-
-
Michigan
-
Novi, Michigan, Egyesült Államok
-
-
New York
-
Flushing, New York, Egyesült Államok
-
Flushing, New York, Egyesült Államok, 11355
-
New York, New York, Egyesült Államok
-
New York, New York, Egyesült Államok, 10029
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Egyesült Államok
-
Philadelphia, Pennsylvania, Egyesült Államok, 19107
-
-
Tennessee
-
Nashville, Tennessee, Egyesült Államok
-
-
Texas
-
Sugar Land, Texas, Egyesült Államok, 77478
-
-
-
-
-
Hong Kong, Hong Kong
-
Kowloon, Hong Kong
-
-
-
-
-
Edmonton, Kanada
-
Toronto, Kanada
-
Vancouver, Kanada
-
-
-
-
-
Daegu, Koreai Köztársaság, 700-721
-
Seoul, Koreai Köztársaság
-
Seoul, Koreai Köztársaság, 135-710
-
Seoul, Koreai Köztársaság, 05505
-
Seoul, Koreai Köztársaság, 03722
-
Seoul, Koreai Köztársaság, 152-703
-
Seoul, Koreai Köztársaság, 06973
-
Seoul, Koreai Köztársaság, 03830
-
-
Gyeonggi-d
-
Goyang, Gyeonggi-d, Koreai Köztársaság
-
-
-
-
-
Milan, Olaszország, 20122
-
-
-
-
-
Barcelona, Spanyolország
-
Majadahonda, Spanyolország
-
-
-
-
-
Chiayi City, Tajvan, 60002
-
Kaohsiung, Tajvan
-
Taipei City, Tajvan, 10002
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Key Inclusion Criteria:
- Must have the ability to understand and sign a written informed consent form; consent must be obtained prior to initiation of study procedures
- Adult male and non-pregnant, non-lactating females
- Documented evidence of chronic hepatitis B virus (HBV) infection previously
- Maintained on tenofovir disoproxil fumarate (TDF) 300 mg once daily for at least 48 weeks, and as monotherapy for chronic hepatitis B for at least 24 weeks with viral suppression (HBV DNA < lower limit of quantitation) for a minimum of 12 weeks prior to screening
- Adequate renal function
- Normal Electrocardiogram
Key Exclusion Criteria:
- Pregnant women or women who are breastfeeding
- Males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study.
- Co-infection with hepatitis C virus (HCV), hepatitis D virus (HDV), or human immunodeficiency virus (HIV)
- Evidence of hepatocellular carcinoma
- Current evidence of, or recent (≤ 5 year) history of clinical hepatic decompensation
Abnormal hematological and biochemical parameters, including:
- Hemoglobin < 10 g/dL
- Absolute neutrophil count < 750/mm^3
- Platelets ≤ 50,000/mm^3
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 × upper limit of the normal (ULN)
- Albumin < 3.0 mg/ dL
- International normalized ratio (INR) > 1.5 × ULN (unless stable on anticoagulant regimen)
- Total bilirubin > 2.5 × ULN
- Received solid organ or bone marrow transplant
- Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (eg, basal cell skin cancer). Individuals under evaluation for possible malignancy are not eligible.
- Currently receiving therapy with immunomodulators (eg, corticosteroids), nephrotoxic agents, or agents capable of modifying renal excretion
- Individuals receiving ongoing therapy with drugs not to be used with TAF or TDF or individuals with a known hypersensitivity to study drugs, metabolites, or formulation excipients
- Current alcohol or substance abuse judged by the investigator to potentially interfere with compliance
- Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements.
- Use of investigational agents within 3 months of screening, unless allowed by the sponsor
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Kettős
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: TAF 25 mg
Double-blind (DB) phase: TAF 25 mg + TDF placebo for up to 53 weeks.
Open-label extension (OLE) phase: TAF 25 mg for up to 52 weeks.
|
25 mg-os tabletta szájon át naponta egyszer
Más nevek:
Tabletta szájon át naponta egyszer
|
Aktív összehasonlító: TDF 300 mg
DB phase: TDF 300 mg + TAF placebo for up to 50 weeks.
OLE phase: TAF 25 mg for up to 52 weeks.
|
25 mg-os tabletta szájon át naponta egyszer
Más nevek:
300 mg-os tabletta szájon át naponta egyszer
Más nevek:
Tabletta szájon át naponta egyszer
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Percentage of Participants With Hepatitis B Virus (HBV) DNA Levels ≥ 20 IU/mL at Week 48, as Determined by the Modified United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm
Időkeret: Week 48
|
The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 48 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:
|
Week 48
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Percentage of Participants With HBV DNA Levels ≥ 20 IU/mL at Week 96, as Determined by the Modified US FDA-Defined Snapshot Algorithm
Időkeret: Week 96
|
The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 96 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:
|
Week 96
|
Percentage of Participants With HBV DNA Levels < 20 IU/mL at Week 48
Időkeret: Weeks 48
|
The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window.
Missing=Failure (M = F) approach was used for analysis.
|
Weeks 48
|
Percentage of Participants With HBV DNA Levels < 20 IU/mL (Target Detected/Not Detected) at Week 48
Időkeret: Week 48
|
The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window.
The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 48, was handled by M = F, and Missing=Excluded (M = E) approaches.
|
Week 48
|
Percentage of Participants With HBV DNA Levels < 20 IU/mL at Week 96
Időkeret: Week 96
|
The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window.
M = F approach was used for analysis.
|
Week 96
|
Percentage of Participants With HBV DNA Levels < 20 IU/mL (Target Detected/Not Detected) at Week 96
Időkeret: Week 96
|
The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window.
The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 96, was handled by Missing=Failure (M = F), and Missing=Excluded (M = E) approaches.
|
Week 96
|
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 48
Időkeret: Week 48
|
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing.
The M = F approach was used for this analysis.
|
Week 48
|
Percentage of Participants With HBeAg Seroconversion at Week 48
Időkeret: Week 48
|
HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit.
The M = F approach was used for this analysis.
|
Week 48
|
Percentage of Participants With HBeAg Loss at Week 96
Időkeret: Week 96
|
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing.
The M = F approach was used for this analysis.
|
Week 96
|
Percentage of Participants With HBeAg Seroconversion at Week 96
Időkeret: Week 96
|
HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit.
The M = F approach was used for this analysis.
|
Week 96
|
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48
Időkeret: Week 48
|
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing.
The M = F approach was used for this analysis.
|
Week 48
|
Percentage of Participants With HBsAg Seroconversion at Week 48
Időkeret: Week 48
|
HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit.
The M = F approach was used for this analysis.
|
Week 48
|
Percentage of Participants With HBsAg Loss at Week 96
Időkeret: Week 96
|
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing.
The M = F approach was used for this analysis.
|
Week 96
|
Percentage of Participants With HBsAg Seroconversion at Week 96
Időkeret: Week 96
|
HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit.
The M = F approach was used for this analysis.
|
Week 96
|
Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 48 (by Central Laboratory and the American Association for the Study of Liver Diseases [AASLD] Criteria)
Időkeret: Week 48
|
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years.
The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males.
M = F approach was used for analysis.
|
Week 48
|
Percentage of Participants With Normalized ALT at Week 48 (by Central Laboratory and AASLD Criteria)
Időkeret: Week 48
|
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years.
The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males.
M = F approach was used for analysis.
|
Week 48
|
Percentage of Participants With Normal ALT at Week 96 (by Central Laboratory and the AASLD Criteria)
Időkeret: Week 96
|
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years.
The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males.
M = F approach was used for analysis.
|
Week 96
|
Percentage of Participants With Normalized ALT at Week 96 (by Central Laboratory and AASLD Criteria)
Időkeret: Week 96
|
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years.
The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males.
M = F approach was used for analysis.
|
Week 96
|
Change From Baseline in FibroTest® Score at Week 48
Időkeret: Baseline; Week 48
|
The FibroTest score is used to assess liver fibrosis.
Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.
Change from baseline was calculated as the value at Week 48 minus the value at Baseline.
|
Baseline; Week 48
|
Change From Baseline in FibroTest® Score at Week 96
Időkeret: Baseline; Week 96
|
The FibroTest score is used to assess liver fibrosis.
Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.
Change from baseline was calculated as the value at Week 96 minus the value at Baseline.
|
Baseline; Week 96
|
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Időkeret: Baseline; Week 48
|
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%.
|
Baseline; Week 48
|
Percent Change From Baseline in Hip BMD at Week 96
Időkeret: Baseline; Week 96
|
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%.
|
Baseline; Week 96
|
Percent Change From Baseline in Spine BMD at Week 48
Időkeret: Baseline; Week 48
|
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%.
|
Baseline; Week 48
|
Percent Change From Baseline in Spine BMD at Week 96
Időkeret: Baseline; Week 96
|
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%.
|
Baseline; Week 96
|
Change From Baseline in Estimated Glomerular Filtration Rate Calculated Using the Cockcroft-Gault Equation (eGFR-CG) at Week 48
Időkeret: Baseline; Week 48
|
Cockcroft-Gault formula is as follows:
Change from baseline was calculated as the value at Week 48 minus the value at Baseline. |
Baseline; Week 48
|
Change From Baseline in eGFR-CG at Week 96
Időkeret: Baseline; Week 96
|
Cockcroft-Gault formula is as follows:
Change from baseline was calculated as the value at Week 96 minus the value at Baseline. |
Baseline; Week 96
|
Együttműködők és nyomozók
Szponzor
Publikációk és hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
- Emésztőrendszeri betegségek
- RNS vírusfertőzések
- Vírusos betegségek
- Fertőzések
- Vérrel terjedő fertőzések
- Fertőző betegségek
- Májbetegségek
- Hepatitis, vírusos, emberi
- Hepadnaviridae fertőzések
- DNS vírusfertőzések
- Enterovírus fertőzések
- Picornaviridae fertőzések
- Hepatitisz B
- Májgyulladás
- Hepatitisz A
- Hepatitis B, krónikus
- Hepatitis, krónikus
Egyéb vizsgálati azonosító számok
- GS-US-320-4018
- 2016-003632-20 (EudraCT szám)
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
IPD megosztási időkeret
IPD-megosztási hozzáférési feltételek
Az IPD megosztását támogató információ típusa
- STUDY_PROTOCOL
- NEDV
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Krónikus hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesMég nincs toborzás
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.IsmeretlenKrónikus hepatitis b
-
Zhongshan Hospital Xiamen UniversityIsmeretlenEgészséges | Krónikus hepatitis B fertőzésKína
-
Brii Biosciences LimitedVir Biotechnology, Inc.Aktív, nem toborzóKrónikus hepatitis B vírusfertőzésSzingapúr, Thaiföld, Ausztrália, Kína, Koreai Köztársaság
-
Tongji HospitalGilead SciencesToborzás
-
Jiangsu HengRui Medicine Co., Ltd.Ismeretlen
-
Changhai HospitalBefejezveKrónikus hepatitis bKína
-
University Hospital, Strasbourg, FranceToborzás
-
Nanfang Hospital of Southern Medical UniversityToborzás
Klinikai vizsgálatok a TAF
-
Gilead SciencesToborzásHIV-1 fertőzésEgyesült Államok, Thaiföld, Uganda, Dél-Afrika
-
Gilead SciencesBefejezveHIV-1 fertőzésEgyesült Államok, Dominikai Köztársaság, Puerto Rico, Thaiföld
-
Gilead SciencesMég nincs toborzás
-
Gilead SciencesBefejezve
-
Gilead SciencesToborzásHIV-1 fertőzésEgyesült Államok, Franciaország, Kanada
-
Gilead SciencesBefejezveHBV | Krónikus HBV fertőzésekKína
-
Shanghai Public Health Clinical CenterYunnan AIDS Care Center; Xixi Hospital of HangzhouAktív, nem toborzó
-
Gilead SciencesBefejezveHBeAg-negatív krónikus hepatitis BHong Kong, Egyesült Államok, Egyesült Királyság, Kanada, Ausztrália, Spanyolország, Tajvan, India, Japán, Lengyelország, Románia, Orosz Föderáció, Koreai Köztársaság, Olaszország, Új Zéland, Franciaország, Pulyka
-
Gilead SciencesBefejezveHBV | Krónikus HBV fertőzésekKína
-
Huashan HospitalThe First Affiliated Hospital with Nanjing Medical University; Peking University... és más munkatársakToborzás